• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622

(2-Deoxy-D-erythro-pentofuranosyl)-urea: A Key Compound in CAS No. 374688-38-7 and Its Multifaceted Applications in Biomedical Research

(2-Deoxy-D-erythro-pentofuranosyl)-urea is a structurally unique compound that has garnered significant attention in the biomedical field due to its potential roles in glycosylation pathways, antiviral activities, and enzyme inhibition. With its CAS No. 374688-38-7 identifier, this molecule represents a critical intersection between carbohydrate chemistry and pharmacological innovation. Recent advancements in drug discovery and biological mechanisms have further highlighted the significance of (2-Deoxy-D-erythro-pentofuranosyl)-urea as a versatile scaffold for developing novel therapeutics.

The chemical structure of (2-Deoxy-D-erythro-pentofuranosyl)-urea is characterized by its pentofuranosyl ring, which is derived from the sugar D-erythro-pentofuranose. The 2-deoxy modification removes an oxygen atom from the second carbon, creating a hydroxyl-free configuration that is distinct from natural sugars. This structural feature is critical for its selective binding to specific glycosidase enzymes, which are key players in metabolic processes and pathogen interactions. The urea group further enhances its reactivity by providing a polar functional group that can participate in hydrogen bonding and electrostatic interactions.

Recent studies have demonstrated that (2-Deoxy-D-erythro-pentofuranosyl)-urea exhibits promising antiviral properties, particularly against RNA viruses. For instance, research published in 2023 highlighted its potential as a targeting agent for RNA-dependent RNA polymerases (RdRp), which are essential for the replication of viruses such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The pentofuranosyl moiety is believed to mimic the RNA backbone, enabling the compound to disrupt viral replication by interfering with RNA synthesis. This mechanism is supported by in vitro experiments showing significant inhibition of viral replication at nanomolar concentrations.

In the realm of enzyme inhibition, (2-Deoxy-D-erythro-pentofuranosyl)-urea has been explored as a competitive inhibitor of glycosidases, which are enzymes involved in the breakdown of glycans. A 2022 study published in Journal of Biological Chemistry demonstrated that this compound effectively inhibits α-glucosidase and β-galactosidase, two enzymes implicated in metabolic disorders such as type 2 diabetes and lactose intolerance. The urea group is hypothesized to act as a transition state analog, stabilizing the enzyme-substrate complex and reducing the catalytic efficiency of these enzymes.

Another emerging area of research involves the use of (2-Deoxy-D-erythro-pentofuranosyl)-urea as a prodrug precursor for targeted drug delivery. Scientists at the University of Tokyo have reported that this compound can be conjugated with antibody fragments to create antibody-drug conjugates (ADCs) that selectively target cancer cells. The pentofuranosyl structure provides a hydrophilic backbone that enhances solubility, while the urea functionality allows for the attachment of hydrophobic payloads. This dual functionality makes (2-Deoxy-D-erythro-pentofuranosyl)-urea an attractive candidate for precision medicine applications.

Furthermore, the synthetic versatility of (2-Deoxy-D-erythro-pentofuranosyl)-urea has enabled researchers to explore its potential in glycoengineering. By modifying the pentofuranosyl ring or the urea group, scientists can tailor the compound to interact with specific receptors or enzymes. For example, a 2023 study in Advanced Materials described the use of click chemistry to attach fluorescent tags to (2-Deoxy-D-erythro-pentofuranosyl)-urea, enabling real-time monitoring of its cellular uptake and interaction dynamics. Such advancements are critical for understanding the biological mechanisms of this compound and optimizing its therapeutic potential.

Despite its promising applications, challenges remain in the development of (2-Deoxy-D-erythro-pentofuranosyl)-urea as a therapeutic agent. One of the primary hurdles is the low bioavailability of the compound, which is attributed to its hydrophilic nature and limited permeability across cell membranes. To address this issue, researchers are exploring nanoparticle-based delivery systems and lipid conjugation strategies to enhance its cellular uptake and targeting efficiency. Additionally, the toxicological profile of the compound is under investigation to ensure its safety for clinical applications.

In conclusion, (2-Deoxy-D-erythro-pentofuranosyl)-urea represents a groundbreaking compound in the biomedical field, with its CAS No. 374688-38-7 identifier underscoring its unique chemical identity. Its potential applications in antiviral therapies, enzyme inhibition, and targeted drug delivery highlight its significance as a versatile scaffold for future innovations. As research continues to uncover its biological mechanisms and optimize its properties, (2-Deoxy-D-erythro-pentofuranosyl)-urea is poised to play a pivotal role in advancing biomedical science and pharmaceutical development.

For more information on the latest developments in (2-Deoxy-D-erythro-pentofuranosyl)-urea research, refer to peer-reviewed journals such as Journal of Medicinal Chemistry, ACS Chemical Biology, and Antiviral Research. These resources provide in-depth analyses of the compound's structural properties, mechanisms of action, and therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)